Roquefort Therapeutics (LSE:ROQ) Debt-to-Asset : 0.00 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Roquefort Therapeutics Debt-to-Asset?

Roquefort Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was £0.00 Mil. Roquefort Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was £0.00 Mil. Roquefort Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was £6.09 Mil. Roquefort Therapeutics's debt to asset for the quarter that ended in Dec. 2023 was 0.00.

Roquefort Therapeutics Debt-to-Asset Historical Data

The historical data trend for Roquefort Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roquefort Therapeutics Debt-to-Asset Chart

Roquefort Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Debt-to-Asset

Roquefort Therapeutics Semi-Annual Data
	Jun21	Jun22	Dec22	Jun23	Dec23
Debt-to-Asset	-	-	-	-	-

Competitive Comparison of Roquefort Therapeutics's Debt-to-Asset

For the Biotechnology subindustry, Roquefort Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Roquefort Therapeutics's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Roquefort Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Roquefort Therapeutics's Debt-to-Asset falls into.

Roquefort Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Roquefort Therapeutics's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	6.089
	=	0.00

Roquefort Therapeutics's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	6.089
	=	0.00

Roquefort Therapeutics (LSE:ROQ) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Roquefort Therapeutics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Roquefort Therapeutics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Roquefort Therapeutics (LSE:ROQ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roquefort Therapeutics PLC (LSE:ROQ) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

ROQAF:USA

Address

85 Great Portland Street, First Floor, London, GBR, W1W 7LT

Website

https://www.roquefortplc.com

Roquefort Therapeutics PLC is engaged in pursuing opportunities to acquire medical biotechnology businesses that are at an early stage in the medical sector including Drug and vaccine development; Diagnostics; Immuno-therapy; and Cell and gene therapies. The principal activity of the Company is to develop pre-clinical next generation medicines focused on hard to treat cancers.

Roquefort Therapeutics (LSE:ROQ) Headlines

No Headlines